Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 14, 2022 07:00 ET | Source: Sio Gene Therapies

Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results

NEW YORK and DURHAM, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal year ended March 31, 2022. Fiscal Fourth...
April 27, 2022 16:25 ET | Source: Sio Gene Therapies

Sio Gene Therapies Provides Corporate Update

-Company Announces Termination of Licensing Agreement for GM1 and GM2 Gene Therapies with the University of Massachusetts-Company has engaged SVB Securities to advise it on a range of strategic...
February 11, 2022 07:00 ET | Source: Sio Gene Therapies

Sio Gene Therapies Announces Corporate Updates and Fiscal Third Quarter 2021 Financial Results

Company prioritizing industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease$81.9...
February 02, 2022 07:00 ET | Source: Sio Gene Therapies

Sio Gene Therapies to Present at the 18th Annual WORLDSymposium™ 2022

NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the...
January 31, 2022 16:01 ET | Source: Sio Gene Therapies

Sio Gene Therapies Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosidosis, Extension of Cash Runway, and CEO Transition

– Company to prioritize industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease,...
November 12, 2021 07:00 ET | Source: Sio Gene Therapies

Sio Gene Therapies Announces Corporate Updates and Fiscal Second Quarter 2021 Financial Results

– Data from AXO-AAV-GM1 Phase 1/2 study demonstrated consistent dose-dependent biomarker improvement including normalization of beta-galactosidase activity in serum and GM1 ganglioside in CSF – ...
November 11, 2021 07:00 ET | Source: Sio Gene Therapies

Sio Gene Therapies Announces Successful Manufacture of Three GMP Batches of AXO-Lenti-PD Gene Therapy for Parkinson’s Disease

- Completed three successful GMP campaigns using suspension-based manufacturing process- All batches achieved target titers and have successfully completed fill and finish- Qualified Person (QP)...
November 01, 2021 07:00 ET | Source: Sio Gene Therapies

Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM2 Gene Therapy in Patients with GM2 Gangliosidosis

- Designation complements previously granted Rare Pediatric Disease and Orphan Drug designations- Enrollment ongoing in the registration-enabling trial of AXO-AAV-GM2 in Tay-Sachs/Sandhoff...
October 21, 2021 17:00 ET | Source: Sio Gene Therapies

Sio Gene Therapies Announces Reorganization of R&D Group

NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of...
October 21, 2021 08:00 ET | Source: Sio Gene Therapies

Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM1 (AAV9-GLB1) Gene Therapy in Patients with GM1 Gangliosidosis

NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of...